1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Gastric Motility Disorder Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Gastric Motility Disorder Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Velusetrag
1.4.3 Ipamorelin
1.4.4 TD-8954
1.4.5 Others
1.5 Market by Application
1.5.1 Global Gastric Motility Disorder Drug Market Share by Application: 2021-2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Home Use
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Gastric Motility Disorder Drug Market
1.8.1 Global Gastric Motility Disorder Drug Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Gastric Motility Disorder Drug Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Gastric Motility Disorder Drug Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Gastric Motility Disorder Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Gastric Motility Disorder Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Gastric Motility Disorder Drug Sales Volume Market Share by Region (2015-2020)
3.2 Global Gastric Motility Disorder Drug Sales Revenue Market Share by Region (2015-2020)
3.3 North America Gastric Motility Disorder Drug Sales Volume
3.3.1 North America Gastric Motility Disorder Drug Sales Volume Growth Rate (2015-2020)
3.3.2 North America Gastric Motility Disorder Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Gastric Motility Disorder Drug Sales Volume
3.4.1 East Asia Gastric Motility Disorder Drug Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Gastric Motility Disorder Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Gastric Motility Disorder Drug Sales Volume (2015-2020)
3.5.1 Europe Gastric Motility Disorder Drug Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Gastric Motility Disorder Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Gastric Motility Disorder Drug Sales Volume (2015-2020)
3.6.1 South Asia Gastric Motility Disorder Drug Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Gastric Motility Disorder Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Gastric Motility Disorder Drug Sales Volume (2015-2020)
3.7.1 Southeast Asia Gastric Motility Disorder Drug Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Gastric Motility Disorder Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Gastric Motility Disorder Drug Sales Volume (2015-2020)
3.8.1 Middle East Gastric Motility Disorder Drug Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Gastric Motility Disorder Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Gastric Motility Disorder Drug Sales Volume (2015-2020)
3.9.1 Africa Gastric Motility Disorder Drug Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Gastric Motility Disorder Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Gastric Motility Disorder Drug Sales Volume (2015-2020)
3.10.1 Oceania Gastric Motility Disorder Drug Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Gastric Motility Disorder Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Gastric Motility Disorder Drug Sales Volume (2015-2020)
3.11.1 South America Gastric Motility Disorder Drug Sales Volume Growth Rate (2015-2020)
3.11.2 South America Gastric Motility Disorder Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Gastric Motility Disorder Drug Sales Volume (2015-2020)
3.12.1 Rest of the World Gastric Motility Disorder Drug Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Gastric Motility Disorder Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Gastric Motility Disorder Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Gastric Motility Disorder Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Gastric Motility Disorder Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Gastric Motility Disorder Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Gastric Motility Disorder Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Gastric Motility Disorder Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Gastric Motility Disorder Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Gastric Motility Disorder Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Gastric Motility Disorder Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Gastric Motility Disorder Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Gastric Motility Disorder Drug Sales Volume Market Share by Type (2015-2020)
14.2 Global Gastric Motility Disorder Drug Sales Revenue Market Share by Type (2015-2020)
14.3 Global Gastric Motility Disorder Drug Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Gastric Motility Disorder Drug Consumption Volume by Application (2015-2020)
15.2 Global Gastric Motility Disorder Drug Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Gastric Motility Disorder Drug Business
16.1 Theravance, Inc.
16.1.1 Theravance, Inc. Company Profile
16.1.2 Theravance, Inc. Gastric Motility Disorder Drug Product Specification
16.1.3 Theravance, Inc. Gastric Motility Disorder Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Targacept, Inc.
16.2.1 Targacept, Inc. Company Profile
16.2.2 Targacept, Inc. Gastric Motility Disorder Drug Product Specification
16.2.3 Targacept, Inc. Gastric Motility Disorder Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Helsinn Healthcare S.A.
16.3.1 Helsinn Healthcare S.A. Company Profile
16.3.2 Helsinn Healthcare S.A. Gastric Motility Disorder Drug Product Specification
16.3.3 Helsinn Healthcare S.A. Gastric Motility Disorder Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Concert Pharmaceuticals, Inc.
16.4.1 Concert Pharmaceuticals, Inc. Company Profile
16.4.2 Concert Pharmaceuticals, Inc. Gastric Motility Disorder Drug Product Specification
16.4.3 Concert Pharmaceuticals, Inc. Gastric Motility Disorder Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 ChironWells GmbH
16.5.1 ChironWells GmbH Company Profile
16.5.2 ChironWells GmbH Gastric Motility Disorder Drug Product Specification
16.5.3 ChironWells GmbH Gastric Motility Disorder Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Gastric Motility Disorder Drug Manufacturing Cost Analysis
17.1 Gastric Motility Disorder Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Gastric Motility Disorder Drug
17.4 Gastric Motility Disorder Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Gastric Motility Disorder Drug Distributors List
18.3 Gastric Motility Disorder Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Gastric Motility Disorder Drug (2021-2026)
20.2 Global Forecasted Revenue of Gastric Motility Disorder Drug (2021-2026)
20.3 Global Forecasted Price of Gastric Motility Disorder Drug (2015-2026)
20.4 Global Forecasted Production of Gastric Motility Disorder Drug by Region (2021-2026)
20.4.1 North America Gastric Motility Disorder Drug Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Gastric Motility Disorder Drug Production, Revenue Forecast (2021-2026)
20.4.3 Europe Gastric Motility Disorder Drug Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Gastric Motility Disorder Drug Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Gastric Motility Disorder Drug Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Gastric Motility Disorder Drug Production, Revenue Forecast (2021-2026)
20.4.7 Africa Gastric Motility Disorder Drug Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Gastric Motility Disorder Drug Production, Revenue Forecast (2021-2026)
20.4.9 South America Gastric Motility Disorder Drug Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Gastric Motility Disorder Drug Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Gastric Motility Disorder Drug by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Gastric Motility Disorder Drug by Country
21.2 East Asia Market Forecasted Consumption of Gastric Motility Disorder Drug by Country
21.3 Europe Market Forecasted Consumption of Gastric Motility Disorder Drug by Countriy
21.4 South Asia Forecasted Consumption of Gastric Motility Disorder Drug by Country
21.5 Southeast Asia Forecasted Consumption of Gastric Motility Disorder Drug by Country
21.6 Middle East Forecasted Consumption of Gastric Motility Disorder Drug by Country
21.7 Africa Forecasted Consumption of Gastric Motility Disorder Drug by Country
21.8 Oceania Forecasted Consumption of Gastric Motility Disorder Drug by Country
21.9 South America Forecasted Consumption of Gastric Motility Disorder Drug by Country
21.10 Rest of the world Forecasted Consumption of Gastric Motility Disorder Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer